BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35023443)

  • 1. Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease.
    Deben DS; Wong DR; van Bodegraven AA
    Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1433-1444. PubMed ID: 35023443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proactive Metabolite Testing in Patients on Thiopurine May Yield Long-Term Clinical Benefits in Inflammatory Bowel Disease.
    Barnes A; Ooi SJ; Lynch KD; Parthasarathy N; Bishara M; Gounder M; Grafton R; Leach P; Bampton P; Sechi A; Ng W; Connor S; van Langenberg D; Mountifield R; Andrews JM
    Dig Dis Sci; 2023 Mar; 68(3):889-896. PubMed ID: 35687221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: thiopurines in inflammatory bowel disease.
    Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
    Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rac1/pSTAT3 expression: A pharmacodynamic marker panel as a first step toward optimization of thiopurine therapy in inflammatory bowel disease patients.
    Deben DS; van Adrichem AJ; Drent R; Puts S; Pelzer KEJM; van Bodegraven AA; Wong DR; Leers MPG
    Cytometry A; 2022 Feb; 101(2):167-176. PubMed ID: 34595833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease.
    Simsek M; Meijer B; Mulder CJJ; van Bodegraven AA; de Boer NKH
    Ther Drug Monit; 2017 Dec; 39(6):584-588. PubMed ID: 29040228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients.
    Deben DS; Creemers RH; van Adrichem AJ; Drent R; Merry AHH; Leers MPG; van Bodegraven AA; Wong DR
    Sci Rep; 2022 Sep; 12(1):15806. PubMed ID: 36138194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
    Teml A; Schaeffeler E; Herrlinger KR; Klotz U; Schwab M
    Clin Pharmacokinet; 2007; 46(3):187-208. PubMed ID: 17328579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key factors associated with 6-thioguanine and 6-methylmercaptopurine nucleotide concentrations in children treated by thiopurine for acute leukaemia and inflammatory bowel disease.
    de Beaumais TA; Lorrain S; Mamhoudi N; Simonin M; Martinez Vinson C; Medard Y; Petit A; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2024 Jan; 90(1):209-219. PubMed ID: 37621013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do clinical and laboratory parameters predict thiopurine metabolism and clinical outcome in patients with inflammatory bowel diseases?
    Frick S; Müller D; Kullak-Ublick GA; Jetter A
    Eur J Clin Pharmacol; 2019 Mar; 75(3):335-342. PubMed ID: 30610277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing thiopurine therapy in inflammatory bowel disease.
    Chevaux JB; Peyrin-Biroulet L; Sparrow MP
    Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A validated HPLC method for the monitoring of thiopurine metabolites in whole blood in paediatric patients with inflammatory bowel disease.
    Cangemi G; Barabino A; Barco S; Parodi A; Arrigo S; Melioli G
    Int J Immunopathol Pharmacol; 2012; 25(2):435-44. PubMed ID: 22697075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical and Sample Preparation Protocol for Therapeutic Drug Monitoring of 12 Thiopurine Metabolites Related to Clinical Treatment of Inflammatory Bowel Disease.
    Pecher D; Dokupilová S; Zelinková Z; Peppelenbosch M; Lučeničová J; Mikušová V; Mikuš P
    Molecules; 2018 Jul; 23(7):. PubMed ID: 30018218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
    Wong DR; Coenen MJ; Vermeulen SH; Derijks LJ; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
    J Crohns Colitis; 2017 Feb; 11(2):175-184. PubMed ID: 27402913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology and pharmacogenetics of thiopurines.
    Sahasranaman S; Howard D; Roy S
    Eur J Clin Pharmacol; 2008 Aug; 64(8):753-67. PubMed ID: 18506437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease: a retrospective observational study.
    Gensmyr-Singer H; Werner M; Karling P
    Therap Adv Gastroenterol; 2024; 17():17562848241228064. PubMed ID: 38384282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
    Spencer E; Norris E; Williams C; Dubinsky MC
    Inflamm Bowel Dis; 2019 Jan; 25(1):142-149. PubMed ID: 29920603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.